Pelotonia awards six grants to Ohio State

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

PELOTONIA awarded six, two-year grants to projects at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital & Richard J. Solove Research Institute.

Pelotonia is a fundraising bicycle tour established in 2009 to raise money for cancer research at Ohio State. In the past four years, 67 OSUCCC – James research teams have received Pelotonia Idea Grants. A total of $650,000 will be awarded in this latest round of grants, with $6.6 million in funding awarded since the program’s inception.

The 2014 Pelotonia Idea Grants funded the following projects: Identifying and Developing New Immunoagents for Cancer Diagnosis and Therapy; Proteasomal Pathway Regulates PTEN Protein Degradation and Promotes Carcinogenesis; A Mass-Spectrometry Approach to Mapping Histone Modification Crosstalk; Develop IL-27 Based Combinational Immunotherapy of Cancer; Ceragenin-based Therapy for Multiple Myeloma; and Defining the Role of Autophagy in Anoikis Resistance and in Peritoneal Carcinomatosis/Sarcomatosis.

YOU MAY BE INTERESTED IN

Despite steady progress in reducing overall cancer mortality rates, cancer incidence in women is rising, according to the American Cancer Society’s “Cancer Statistics, 2025” report. Incidence rates in women 50-64 years of age have surpassed those in men, and rates in women under 50 are now 82% higher than their male counterparts, up from 51% higher in 2002. In 2021, for the first time, lung cancer incidence was higher in women under 65 than in men. 
Over the past five years, Cedars-Sinai Cancer has built an integrated, regional system designed to provide cancer care close to where patients live and work. This model of care, directed by an academic medical center to patients at the community level, proved to be the best possible approach to supporting patients in our 11-million-person catchment area during the worst fire disaster in California history. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login